Compass Therapeutics, Inc.
CMPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $199 | $198 | $529 | $199 |
| - Cash | $43 | $24 | $35 | $145 |
| + Debt | $7 | $2 | $3 | $4 |
| Enterprise Value | $162 | $176 | $497 | $59 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$55 | -$48 | -$40 | -$80 |
| % Margin | -6,455.5% | – | – | – |
| Net Income | -$49 | -$42 | -$39 | -$82 |
| % Margin | -5,808.8% | – | – | – |
| EPS Diluted | -0.36 | -0.33 | -0.35 | -1.31 |
| % Growth | -9.1% | 5.7% | 73.3% | – |
| Operating Cash Flow | -$45 | -$41 | -$34 | -$20 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$2 |
| Free Cash Flow | -$45 | -$41 | -$34 | -$21 |